Overview

Efficacy and Safety of Pazopanib Monotherapy After First-line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Asian Women

Status:
Completed
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
This is a study to determine whether therapy with pazopanib is effective and safe in Asian women with epithelial ovarian, fallopian tube or primary peritoneal cancer whose cancer has not progressed on first-line chemotherapy.
Phase:
Phase 2
Details
Lead Sponsor:
GlaxoSmithKline